Cover Image
市場調查報告書

大日本住友製藥的產品平台分析

Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321961
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
大日本住友製藥的產品平台分析 Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 102 Pages
簡介

大日本住友製藥正在開發、製造並商品化中樞神經系統(CNS),心血管系統,糖尿病,癌症,感染疾病等領域的各種醫藥產品。同時也提供動物用醫藥品,食品添加物,診斷用藥,研究用材料等,更在研究本部進行創新的新藥研究。

本報告提供大日本住友製藥 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

大日本住友製藥 基本資料

  • 大日本住友製藥 概要
  • 主要資訊
  • 企業資料

大日本住友製藥 :R&D概要

  • 主要的治療範圍

大日本住友製藥 :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

大日本住友製藥 :開發中產品概況

  • 後期階段產品開發中產品
    • 登記申請前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

大日本住友製藥 :藥物簡介

  • amrubicin hydrochloride
  • blonanserin
  • droxidopa
  • lurasidone hydrochloride
  • ranirestat
  • vatiquinone
  • afacifenacin
  • DSP-6952
  • obeticholic acid
  • zonisamide
  • EPI-589
  • WT-2725
  • WT-4869
  • DSP-0011
  • DSR-6434
  • NEP-28
  • SM-276001
  • SM-295291
  • SM-324405
  • SM-369926
  • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia
  • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection
  • Small Molecules to Activate Translocator Protein for Anxiety
  • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis
  • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation
  • Small Molecules to Target Ras Signaling Pathway for Cancer
  • Apoptosis Inhibitor Of Macrophages
  • HLS-001
  • Small Molecule to Antagonize GCGR for Type 2 Diabetes
  • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
  • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
  • Small Molecules to Inhibit CaMKII for Undisclosed Indication
  • Small Molecules to Inhibit mPGES-1 for Inflammation

大日本住友製藥 :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

大日本住友製藥 :最新的開發平台資訊

大日本住友製藥 :中止開發的計劃

大日本住友製藥 :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • emapunil
    • rafabegron
    • ceftaroline fosamil
    • DSP-0565
    • DSP-3025
    • DSP-7238
    • DSP-9599
    • KGA-3235
    • limaprost
    • rafabegron
    • ranirestat
    • resequinil
    • rimacalib
    • SEP-225425
    • SEP-226332
    • SEP-227162
    • SEP-227900
    • SMP-028
    • SMP-797

大日本住友製藥 :企業理念

大日本住友製藥 :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07612CDB

Summary

Global Markets Direct's, 'Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Sumitomo Dainippon Pharma Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sumitomo Dainippon Pharma Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sumitomo Dainippon Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sumitomo Dainippon Pharma Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sumitomo Dainippon Pharma Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Sumitomo Dainippon Pharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sumitomo Dainippon Pharma Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sumitomo Dainippon Pharma Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sumitomo Dainippon Pharma Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sumitomo Dainippon Pharma Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sumitomo Dainippon Pharma Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sumitomo Dainippon Pharma Co., Ltd. Snapshot
    • Sumitomo Dainippon Pharma Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Sumitomo Dainippon Pharma Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products Glance
    • Sumitomo Dainippon Pharma Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co., Ltd. - Drug Profiles
    • amrubicin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • blonanserin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lurasidone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranirestat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • zonisamide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vatiquinone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • afacifenacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-6952
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obeticholic acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-7888
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WT-4869
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EPI-589
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WT-2725
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-0011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-6434
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-71167
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-98776
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEP-28
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-276001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-295291
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-324405
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-369926
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Translocator Protein for Anxiety
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target Ras Signaling Pathway for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit Apoptosis of Macrophages for Metabolic Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSR-17759
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HLS-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit mPGES-1 for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Analysis
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Target
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Route of Administration
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Molecule Type
    • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action
  • Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates
  • Sumitomo Dainippon Pharma Co., Ltd. - Dormant Projects
  • Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • emapunil
      • rafabegron
      • ceftaroline fosamil
      • DSP-0565
      • DSP-3025
      • DSP-7238
      • DSP-9599
      • KGA-3235
      • limaprost
      • rafabegron
      • ranirestat
      • resequinil
      • rimacalib
      • SEP-225425
      • SEP-226332
      • SEP-227162
      • SEP-227900
      • SMP-028
      • SMP-797
  • Sumitomo Dainippon Pharma Co., Ltd. - Company Statement
  • Sumitomo Dainippon Pharma Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sumitomo Dainippon Pharma Co., Ltd., Key Information
  • Sumitomo Dainippon Pharma Co., Ltd., Key Facts
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Indication, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pre-Registration, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Phase III, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Phase II, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Phase I, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Preclinical, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Discovery, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Target, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Route of Administration, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Molecule Type, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Dormant Developmental Projects,2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products, 2015
  • Sumitomo Dainippon Pharma Co., Ltd., Other Locations
  • Sumitomo Dainippon Pharma Co., Ltd., Subsidiaries

List of Figures

  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Stage of Development, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top